Evogene Completes First-In-Human Phase 1 Clinical Study Of BMC128, Rationally-Designed Live Bacterial Product Developed By Its Subsidiary, Biomica, In Combination With Nivolumab In Patients With Advanced Solid Tumors

Loading news article.

Evogene Completes First-In-Human Phase 1 Clinical Study Of BMC128, Rationally-Designed Live Bacterial Product Developed By Its Subsidiary, Biomica, In Combination With Nivolumab In Patients With Advanced Solid Tumors | WAPE

Evogene Completes First-In-Human Phase 1 Clinical Study Of BMC128, Rationally-Designed Live Bacterial Product Developed By Its Subsidiary, Biomica, In Combination With Nivolumab In Patients With Advanced Solid Tumors

Article summary

Related companies

Comments —